Brought to you by 
Abraxis buys AstraZeneca's anesthetic and analgesic lines
16 Nov 2022
Executive Summary
Abraxis has announced that it will acquire AstraZeneca's US branded anesthetic and analgesic injectable lines to boost its own injectables business.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abraxis buys AstraZeneca's anesthetic and analgesic lines
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice